tetano
Editor, Senior Moderator
Euro Surveill. 2018 Feb;23(5). doi: 10.2807/1560-7917.ES.2018.23.5.18-00035.
[h=1]Early season co-circulation of influenza A(H3N2) and B(Yamagata): interim estimates of 2017/18 vaccine effectiveness, Canada, January 2018.[/h] Skowronski DM[SUP]1,[/SUP][SUP]2[/SUP], Chambers C[SUP]2[/SUP], De Serres G[SUP]3,[/SUP][SUP]4,[/SUP][SUP]5[/SUP], Dickinson JA[SUP]6[/SUP], Winter AL[SUP]7[/SUP], Hickman R[SUP]2[/SUP], Chan T[SUP]2[/SUP], Jassem AN[SUP]1,[/SUP][SUP]2[/SUP], Drews SJ[SUP]8,[/SUP][SUP]9[/SUP], Charest H[SUP]5[/SUP], Gubbay JB[SUP]10,[/SUP][SUP]7[/SUP], Bastien N[SUP]11[/SUP], Li Y[SUP]11[/SUP], Krajden M[SUP]1,[/SUP][SUP]2[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Using a test-negative design, we assessed interim vaccine effectiveness (VE) for the 2017/18 epidemic of co-circulating influenza A(H3N2) and B(Yamagata) viruses. Adjusted VE for influenza A(H3N2), driven by a predominant subgroup of clade 3C.2a viruses with T131K + R142K + R261Q substitutions, was low at 17% (95% confidence interval (CI): -14 to 40). Adjusted VE for influenza B was higher at 55% (95% CI: 38 to 68) despite prominent use of trivalent vaccine containing lineage-mismatched influenza B(Victoria) antigen, suggesting cross-lineage protection.
[h=4]KEYWORDS:[/h] Influenza; genomics; influenza virus; mid-season; vaccine effectiveness; vaccine-preventable diseases; vaccines and immunisation
PMID: 29409570 DOI: 10.2807/1560-7917.ES.2018.23.5.18-00035
Free full text
[h=1]Early season co-circulation of influenza A(H3N2) and B(Yamagata): interim estimates of 2017/18 vaccine effectiveness, Canada, January 2018.[/h] Skowronski DM[SUP]1,[/SUP][SUP]2[/SUP], Chambers C[SUP]2[/SUP], De Serres G[SUP]3,[/SUP][SUP]4,[/SUP][SUP]5[/SUP], Dickinson JA[SUP]6[/SUP], Winter AL[SUP]7[/SUP], Hickman R[SUP]2[/SUP], Chan T[SUP]2[/SUP], Jassem AN[SUP]1,[/SUP][SUP]2[/SUP], Drews SJ[SUP]8,[/SUP][SUP]9[/SUP], Charest H[SUP]5[/SUP], Gubbay JB[SUP]10,[/SUP][SUP]7[/SUP], Bastien N[SUP]11[/SUP], Li Y[SUP]11[/SUP], Krajden M[SUP]1,[/SUP][SUP]2[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Using a test-negative design, we assessed interim vaccine effectiveness (VE) for the 2017/18 epidemic of co-circulating influenza A(H3N2) and B(Yamagata) viruses. Adjusted VE for influenza A(H3N2), driven by a predominant subgroup of clade 3C.2a viruses with T131K + R142K + R261Q substitutions, was low at 17% (95% confidence interval (CI): -14 to 40). Adjusted VE for influenza B was higher at 55% (95% CI: 38 to 68) despite prominent use of trivalent vaccine containing lineage-mismatched influenza B(Victoria) antigen, suggesting cross-lineage protection.
[h=4]KEYWORDS:[/h] Influenza; genomics; influenza virus; mid-season; vaccine effectiveness; vaccine-preventable diseases; vaccines and immunisation
PMID: 29409570 DOI: 10.2807/1560-7917.ES.2018.23.5.18-00035
Free full text